Table 3.
Potential HBV Therapies in the Pipeline With Known Site of Action
| Site of Action | Drug | Company | Status |
|---|---|---|---|
| Antiviral | |||
| Entry inhibitor | Myrcludex B | Hepatera/MYR GmbH | Phase 2 |
| cccDNA inhibitor | Preclinical | ||
| RNA silencers | ARC-520/-521 | Arrowhead | Terminated |
| ARB-1467 | Arbutus | Phase 2 | |
| ARB-1740 | Arbutus | Preclinical | |
| ALN-HBV | Alnylam | Phase 1/2 | |
| GSK 3228836 | GlaxoSmithKline/Ionis | Phase 1 | |
| Core protein inhibitors | AL-3778 | Alios/Johnson & Johnson | Phase 1/2 |
| ABI-H0731 | Assembly Biosciences | Phase 1 | |
| BAY 41-4109 | AiCuris (Germany) | Phase 1 | |
| GLS4 | HEC | Phase 1 | |
| JNJ-56136379 | Johnson & Johnson | Phase 1 | |
| AB-423 | Arbutus | Preclinical | |
| HBsAg release inhibitors | REP 2139 | Replicor | Phase 2 |
| REP 2165 | Replicor | Phase 2 | |
| Immunomodulators | |||
| TLR-7 agonist | GS-9620 | Gilead Sciences | Phase 2 |
| Therapeutic vaccines | GS-4774 | Gilead Sciences | Complete phase 2 |
| ABX 203 | ABIVAX (France) | Phase 2/3 | |
| AIC649 | AiCuris (Germany) | Phase 1 | |
| FB-02.2 | Altimmune | Phase 1 | |
| INO-1800 | Inovio | Phase 1 | |
| TG1050 | Transgene (France) | Phase 1 | |
| Small molecules | |||
|
SB 9200 | Spring Bank Pharmaceuticals | Phase 2 |
|
Birinapant | TetraLogic | Terminated |
|
PD-1/PDL-2 mAb | Merck Sharp and Dohme; Bristol-Myers Squibb | |
| CTLA-4 mAb | |||
cccDNA, covalently closed circular DNA; CTLA-4, cytotoxic T-lymphocyte-associated protein 4; HBsAg, hepatitis B surface antigen; HBV, hepatitis B virus; mAb, monoclonal antibody; PD-1, programmed cell death protein 1; PDL-2, programmed death-ligand 2; RIG-1 NOD2, retinoic acid-inducible gene I nucleotide-binding oligomerization domain-containing protein 2; SMAC, second mitochondrial activator of caspase; TLR, toll-like receptor.